Browsing Tag
Biologics
17 posts
Is viral vector therapy finally gaining traction in chemotherapy-resistant pediatric tumors?
Theriva’s APAO 2026 data shows viral–chemotherapy synergy in eye tumors. Find out what VCN-01 signals for pediatric oncology's biologics future.
How Hansa Biopharma’s imlifidase could redefine access for hardest-to-match transplant candidates
Hansa Biopharma seeks FDA approval for imlifidase to expand transplant eligibility in high-risk ESRD patients. See what this filing means for U.S. access.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
AstraZeneca (LSE: AZN) goes big on U.S. supply chain with latest $2bn manufacturing push
AstraZeneca invests $2B in Maryland to expand biologics and rare disease drug manufacturing. Find out what this means for U.S. jobs and the pharma supply chain.
Nektar Therapeutics (NASDAQ: NKTR) rezpegaldesleukin shows dual action in skin and asthma — is this a pipeline turning point?
Nektar Therapeutics’ rezpegaldesleukin delivers dual efficacy in dermatitis and asthma in Phase 2b REZOLVE-AD trial. See how this Treg-based therapy is changing the game.
Is Johnson & Johnson quietly building a new autoimmune franchise around FcRn inhibition?
Johnson & Johnson is expanding nipocalimab into multiple autoimmune indications. Find out if FcRn inhibition is the foundation of its next blockbuster franchise.
UCB’s BIMZELX shows sustained inflammation control at three years in psoriatic arthritis and axial spondyloarthritis
Discover how UCB’s BIMZELX three-year data show lasting inflammation control in PsA and axSpA—find out what’s next for the treatment landscape.
Tezspire gains FDA approval for CRSwNP, expanding AstraZeneca and Amgen’s reach in inflammatory airway diseases
Tezspire gets FDA approval for chronic rhinosinusitis with nasal polyps. See how AstraZeneca and Amgen are expanding the respiratory biologics frontier.
Amgen and AstraZeneca win FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Find out how Amgen and AstraZeneca’s Tezspire approval for nasal polyps redefines biologic therapy and reshapes investor confidence today.
Why Leo Pharma’s completed Spevigo deal with Boehringer could reshape rare skin disease care
Leo Pharma completes its acquisition of Spevigo® from Boehringer Ingelheim. Learn how this rare disease drug strengthens its dermatology growth strategy.